Literature DB >> 18157495

Primary antiphospholipid syndrome in Latin American mestizo patients: clinical and immunologic characteristics and comparison with European patients.

Rossana Mejía-Romero1, Mario García-Carrasco, Claudio Galarza-Maldonado, Pedro Santos, Claudia Mendoza-Pinto, Ricardo O Escárcega, Salvador Salinas-Saldivar, Elena Soto-Vega, Aurelio López-Colombo, Ricard Cervera.   

Abstract

A great variety of clinical and immunological features have been described in patients with the antiphospholipid syndrome (APS), but information on their prevalence and characteristics in Latin American mestizo patients with the primary APS is scarce. To analyze the prevalence and characteristics of the main clinical and immunological manifestations in a cohort of patients with primary APS of mestizo origin from Latin America and to compare them with the European white patients, clinical and serological characteristics of 100 patients with primary APS from Colombia, Mexico, and Ecuador were collected in a protocol form that was identical to that used to study the "Euro-Phospholipid" cohort. The cohort consisted of 92 female patients (92.0%) and eight (8.0%) male patients. They were all mestizos. The most common manifestations were deep vein thrombosis (DVT; 23.0%), livedo reticularis (18.0%), migraine (18.0%), and stroke (18.0%). The most common pregnancy morbidity was early pregnancy losses (54.1% of pregnancies). Several clinical manifestations were more prevalent in the Latin American mestizo than in the European patients (transient global amnesia, pulmonary microthrombosis, arthralgias, and early pregnancy losses) and vice-versa (DVT, stroke, pulmonary embolism, and thrombocytopenia). Latin American mestizo patients with primary APS have a wide variety of clinical and immunological manifestations with several differences in their prevalence in comparison with European white patients.

Entities:  

Mesh:

Year:  2007        PMID: 18157495     DOI: 10.1007/s10067-007-0818-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  22 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome.

Authors:  Ilan Krause; Miri Blank; Abigail Fraser; Margalit Lorber; Ludmilla Stojanovich; Josef Rovensky; Yehuda Shoenfeld
Journal:  Immunobiology       Date:  2005-10-21       Impact factor: 3.144

3.  The 'primary' antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients.

Authors:  J Font; A López-Soto; R Cervera; J Balasch; L Pallarés; M Navarro; X Bosch; M Ingelmo
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

4.  Clinical study and follow-up of 100 patients with the antiphospholipid syndrome.

Authors:  F J Muñoz-Rodriguez; J Font; R Cervera; J C Reverter; D Tàssies; G Espinosa; A López-Soto; F Carmona; J Balasch; A Ordinas; M Ingelmo
Journal:  Semin Arthritis Rheum       Date:  1999-12       Impact factor: 5.532

Review 5.  Pulmonary manifestations in antiphospholipid syndrome.

Authors:  Ljudmila Stojanovich
Journal:  Autoimmun Rev       Date:  2006-03-03       Impact factor: 9.754

6.  Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: comparison between Colombians and Spaniards.

Authors:  E Cucurull; L R Espinoza; E Mendez; J F Molina; J Molina; J Ordi-Ros; A E Gharavi
Journal:  Lupus       Date:  1999       Impact factor: 2.911

7.  The "primary" antiphospholipid syndrome: major clinical and serological features.

Authors:  R A Asherson; M A Khamashta; J Ordi-Ros; R H Derksen; S J Machin; J Barquinero; H H Outt; E N Harris; M Vilardell-Torres; G R Hughes
Journal:  Medicine (Baltimore)       Date:  1989-11       Impact factor: 1.889

8.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

9.  Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients.

Authors:  J L Vianna; M A Khamashta; J Ordi-Ros; J Font; R Cervera; A Lopez-Soto; C Tolosa; J Franz; A Selva; M Ingelmo
Journal:  Am J Med       Date:  1994-01       Impact factor: 4.965

10.  Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

Authors:  E N Harris; A E Gharavi; S P Patel; G R Hughes
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

View more
  3 in total

Review 1.  Antiphospholipid syndrome and the brain in pediatric and adult patients.

Authors:  E Muscal; R L Brey
Journal:  Lupus       Date:  2010-04       Impact factor: 2.911

2.  Pregnancy outcomes of antiphospholipid syndrome: In a low resource South Asian setting.

Authors:  C N Wijeyaratne; Sla Galappaththi; E Palipane; Dbia Jayawardane; S H Dodampahala; M N Tudawe; L V Gooneratne; R de Silva; D Ratnayake; S L Seneviratne
Journal:  Obstet Med       Date:  2016-03-17

Review 3.  High prevalence of prothrombotic abnormalities in multifocal osteonecrosis: description of a series and review of the literature.

Authors:  Jose A Gómez-Puerta; Pilar Peris; Joan Carles Reverter; Gerard Espinosa; Angeles Martinez-Ferrer; Ana Monegal; Juan Monteagudo; Dolors Tàssies; Nuria Guañabens
Journal:  Medicine (Baltimore)       Date:  2013-11       Impact factor: 1.889

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.